Masimo Co. (NASDAQ:MASI) Receives $188.25 Consensus Price Target from Analysts

Shares of Masimo Co. (NASDAQ:MASIGet Rating) have been given a consensus recommendation of “Moderate Buy” by the ten research firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $188.25.

A number of equities analysts recently issued reports on MASI shares. Jefferies Financial Group started coverage on shares of Masimo in a research note on Wednesday, October 12th. They issued a “buy” rating and a $180.00 price target for the company. StockNews.com started coverage on shares of Masimo in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Needham & Company LLC raised their target price on shares of Masimo from $149.00 to $173.00 and gave the company a “buy” rating in a research note on Monday, December 5th. Stifel Nicolaus raised their target price on shares of Masimo from $162.00 to $172.00 and gave the company a “buy” rating in a research note on Monday, September 12th. Finally, BTIG Research raised shares of Masimo from a “neutral” rating to a “buy” rating and set a $180.00 target price for the company in a research note on Thursday, December 15th.

Masimo Stock Performance

Masimo stock opened at $154.35 on Friday. The company has a current ratio of 2.12, a quick ratio of 1.28 and a debt-to-equity ratio of 0.76. The firm has a 50-day moving average of $139.59 and a 200-day moving average of $141.76. The firm has a market cap of $8.11 billion, a P/E ratio of 51.11 and a beta of 0.86. Masimo has a 1-year low of $108.89 and a 1-year high of $262.28.

Masimo (NASDAQ:MASIGet Rating) last released its quarterly earnings results on Tuesday, November 8th. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.08. Masimo had a net margin of 9.78% and a return on equity of 18.04%. The company had revenue of $549.30 million during the quarter, compared to the consensus estimate of $533.96 million. Sell-side analysts expect that Masimo will post 4.45 EPS for the current year.

Insider Activity at Masimo

In other news, CEO Joe E. Kiani purchased 7,784 shares of Masimo stock in a transaction that occurred on Friday, November 11th. The stock was bought at an average price of $129.27 per share, with a total value of $1,006,237.68. Following the completion of the transaction, the chief executive officer now directly owns 7,784 shares of the company’s stock, valued at $1,006,237.68. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Joe E. Kiani purchased 7,784 shares of Masimo stock in a transaction that occurred on Friday, November 11th. The stock was bought at an average price of $129.27 per share, with a total value of $1,006,237.68. Following the completion of the transaction, the chief executive officer now directly owns 7,784 shares of the company’s stock, valued at $1,006,237.68. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Joe E. Kiani purchased 7,040 shares of Masimo stock in a transaction that occurred on Thursday, December 15th. The shares were purchased at an average cost of $144.79 per share, with a total value of $1,019,321.60. Following the transaction, the chief executive officer now directly owns 46,818 shares of the company’s stock, valued at $6,778,778.22. The disclosure for this purchase can be found here. Insiders bought 46,818 shares of company stock valued at $5,992,495 over the last 90 days. Corporate insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Masimo

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Masimo by 1.5% in the first quarter. Vanguard Group Inc. now owns 4,775,660 shares of the medical equipment provider’s stock worth $695,050,000 after purchasing an additional 71,918 shares during the last quarter. Politan Capital Management LP purchased a new stake in Masimo in the third quarter worth approximately $656,234,000. FMR LLC boosted its holdings in Masimo by 1.7% in the second quarter. FMR LLC now owns 2,104,939 shares of the medical equipment provider’s stock worth $275,052,000 after purchasing an additional 35,438 shares during the last quarter. Nomura Holdings Inc. purchased a new stake in Masimo in the second quarter worth approximately $242,537,000. Finally, State Street Corp boosted its holdings in Masimo by 1.6% in the first quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider’s stock worth $251,928,000 after purchasing an additional 27,261 shares during the last quarter. Hedge funds and other institutional investors own 87.67% of the company’s stock.

About Masimo

(Get Rating)

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

See Also

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.